TORONTO, June 10, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, is pleased to announce that the first commercial benign prostatic hyperplasia ("BPH") treatment utilizing the TULSA-PRO system's new TULSA-AI Volume Reduction Module was successfully conducted yesterday by Naveen Kella, M.D., Founder of ...

Core Points - Profound Medical Corp. held its Annual General and Special Meeting of Shareholders, with 20,587,011 common shares represented, accounting for 68.5% of the outstanding shares [1][2] - All matters presented to shareholders were approved by the requisite majority [2] Election of Directors - All six nominees for the board of directors were elected with the following voting results: - Arun Menawat: 11,147,209 votes (94.536% for) [3] - Brian Ellacott: 11,048,084 votes (93.695% for) [3] - Cynthia Lavoie: 11,438,299 votes (97.005% for) [3] - Murielle Lortie: 11,291,509 votes (95.76% for) [3] - Arthur Rosenthal: 10,899,784 votes (92.438% for) [3] - Kris Shah: 11,040,268 votes (93.629% for) [3] Other Matters - Shareholders approved the appointment of PricewaterhouseCoopers LLP as the auditor until the next annual meeting [4] - An ordinary resolution was passed approving all unallocated options under the Company's share option plan [4] Company Overview - Profound Medical Corp. is a commercial-stage medical device company focused on customizable, incision-free therapies for the ablation of diseased tissue [5] - The company is commercializing TULSA-PRO®, a technology that combines real-time MRI, AI-enhanced planning, and robotically driven ultrasound for prostate disease treatment [6] - TULSA-PRO® is designed to preserve urinary continence and sexual function while effectively treating prostate tissue [6] - Profound is also commercializing Sonalleve®, a platform for treating uterine fibroids and palliative pain from bone metastases, with various regulatory approvals [7]

TORONTO, May 08, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, today reported unaudited financial results for the first quarter ended March 31, 2025. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with U.S. generally accepte ...

Core Insights - Profound Medical Corp. is a commercial-stage medical device company focused on customizable, incision-free therapies for ablation of diseased tissue [3] Company Overview - Profound Medical is commercializing TULSA-PRO®, a technology that integrates real-time MRI, robotically-driven transurethral ultrasound, and closed-loop temperature feedback control for prostate disease treatment [4] - The TULSA procedure is designed to treat a range of prostate conditions, including low-, intermediate-, and high-risk prostate cancer, benign prostatic hyperplasia (BPH), and salvage therapy for radio-recurrent localized prostate cancer [4] - TULSA is a single-session procedure that preserves urinary continence and sexual function while effectively targeting prostate tissue through precise heating [4] - Profound is also commercializing Sonalleve®, a therapeutic platform for treating uterine fibroids and palliative pain from bone metastases, with approvals in multiple regions including CE marking and FDA clearance [5] Upcoming Events - Management will present a business update at the 2025 Bloom Burton & Co. Healthcare Investor Conference on May 6, 2025 [1] - The presentation will be available for live broadcast and archived on the company's website [2]

– First Level 1 study comparing an emerging technology head-to-head with RP in men with prostate cancer – – TULSA had no blood loss and no overnight stay, along with reduced post-procedure pain, and more rapid recovery to baseline activities and overall health – TORONTO, April 29, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the a ...